From: Biology-driven cancer drug development: back to the future
Drug | Brand name | Drug target* | Cancer types |
---|---|---|---|
In clinical use | |||
Bevacizumab | Avastin | VEGF | Colorectal, non-small cell lung, breast, renal |
Bortezomib | Velcade | Proteasome | Myeloma, lymphoma |
Celecoxib | Onsenal | COX2 | Familial adenomatous polyposis |
Erlotinib | Tarceva | ||
Gefitinib | Iressa | EGFR | Non-small cell, lung, colorectal, head and neck |
Cetuximab | Erbitux | ||
Panitumumab | Vectibix | ||
Imatinib | Gleevec | ||
Dasatinib | Sprycel | BCR-ABL, cKIT, PDGFR | Leukemia, gastrointestinal |
Nilotinib | Tasigna | ||
Methotrexate | DHFR | Multiple cancer types | |
RAD001 | Certican | mTOR | Renal |
Temirolimus | Toricel | ||
Sorafenib | Nexavar | VEGFR, RAF, cKIT, PDGFR | Renal, hepatic |
Sunitinib | Sutent | ||
Topotecan | Hycamtin | Topoisomerase I | Multiple cancer types |
Irinotecan | Camptosar | ||
Trastuzumab | Herceptin | ERBB2 | Breast |
Lapatinib | Tykerb | HER2, EGFR | Breast |
Tamoxifen | Nolvadex | ERα | Breast |
Exemestane | Aromasin | ||
Anastrozole | Arimidex | Aromatase cytochrome P450 | Breast |
Letrozole | Femara | ||
Rituximab | MabThera | CD20 | Lymphoma |
Tositumomab | Bexxar | ||
In development | |||
17AAG | HSP90 | ||
ABT-737, ABT-263, Obatoclax | BCL-XL, BCL-2 | ||
Alvocidib | CDKs | ||
Olaparib, AG014699 | PARP1/2 | ||
BEZ235 | PI3K | ||
GRN163L | hTERT | ||
Mapatumumab | TRAIL Receptor | ||
Nutlin-3 | MDM2 | ||
PLX4032 | BRAF | ||
GDC-0449 | SMO | ||
PF-0477736 | CHK1 |